Project Title: Adenovirus-vectored nasal anthrax vaccine
                     ;     National Institutes of Health
                     ;     Department of Health and Human Services
Grant Number: 1 UC1 AI067198-01
Issue Date: 9/15/2005
Award Amount: $2,435,173
Principal Investigator: Tang, De-Chu C., PH.D.

Project Title: Replication-Defective Adenovirus-Vectored Pandemic Influenza
                     ;     National Institutes of Health
                     ;     Department of Health and Human Services
Grant Number: 1 UC1 AI067205-01
Issue Date: 9/20/2005
Award Amount: $3,000,000
Principal Investigator: Trent, Dennis W., Ph. D.

E. coli-Vectored Tetanus and Anthrax Vaccine Patch Protective in Mice - July 4, 2006
Link to article

Vaxin executives eye Taiwan for money, location incentives - February 17, 2006
Link to article

(Taiwan) Vaxin's approach a 'new vision' for the vaccine industry: CEO (Taiwan Life Sciences Weekly - January 16, 2006
Link to article

Vaxin’s technology at the forefront of national development trends for 2004 - January 11, 2005
Link to article

New targets for anthrax remedies (SeparationsNOW.com)-December 2004
Link to article

Federal Funding is Key to vaccine producer Vaxin (Birmingham Business Journal) -Oct. 22, 2004
Link to article

Data from Vaxin’s First Flu Vaccine Clinical Trial Reported in Journal “Vaccine” -Jan. 11, 2005
Birmingham, AL – January 11, 2005 – Vaxin Inc., a privately-held biotechnology company, has demonstrated, in a Phase I human clinical study, that the company’s recombinant influenza vaccine provides a potential alternative to traditional flu vaccines. Published in the January 11, 2005 issue of the journal Vaccine (volume 23, issue 8, pages 1029-1036), the paper is entitled “Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans.” The authors conclude that Vaxin’s novel flu vaccine, which is produced in cell culture, was immunogenic and well tolerated by human volunteers.
Link to whole article

Revolutionary Flu Vaccine in Development by Vaxin Inc.-Oct. 11, 2004
Birmingham, AL – October 11, 2004 – In the midst of mounting concerns about shortages of flu vaccine supplies and worries about the deadly avian flu virus and its potential to cause a pandemic, Vaxin Inc., a privately-held biotechnology company in Birmingham, Alabama, is quietly developing a revolutionary new flu vaccine. The Vaxin influenza vaccine differs from traditional flu vaccines in two important ways: its method of manufacture and its method of delivery; both of which convey potentially significant advantages over traditional flu vaccines.
Link to whole article

Crucell And Vaxin Announce PER.C6 Licensing Agreement-Sept. 13, 2004
Birmingham, AL – Sept. 13, 2004 – Vaxin Inc., an emerging biotechnology company developing new vaccines for influenza, anthrax, respiratory syncytial virus (RSV) and other diseases, announced today that it has entered into a license agreement with Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL). This non-exclusive license agreement allows Vaxin to use Crucell’s PER.C6® cell line for the development, manufacture and commercialization of its recombinant adenoviral vaccines against certain respiratory viruses.
Link to whole article

Crucell Announces PER.C6(R) Licensing Agreement with Vaxin for Adenoviral Vaccine-Sept. 13, 2004
Leiden, The Netherlands, September 13, 2004 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL) announced today that it has signed a non-exclusive PER.C6® technology license agreement with Vaxin, Inc. of Birmingham, Alabama. This license agreement allows Vaxin to use PER.C6® technology for research, development and commercialization of recombinant adenoviral vaccines against certain respiratory viruses.
Link to whole article